A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Upon learning it was Tetsu, Baachiyo attempts to force himself on the officer before the Dekarangers arrest the alien. Baachiyo is voiced by Motomu Kiyokawa (清川元夢, Kiyokawa Motomu) in his immature form and Taiki Matsuno (松野 太紀, Matsuno Taiki) in his adult form. Spiritian Byoi (スピリト星人ビョーイ, Supirito Seijin Byōi): A gas-based criminal from Planet Spirit who is capable of possessing other beings. He secretly possesses Ban, but is forced out by Hakutaku. Byoi retaliates by piloting a cyclops-themed flight-capable Kaijuki called Hunter Jet (ハンタージェット, Hantā Jetto), but is deleted by Deka Bike Robo. Byoi is voiced by Katsumi Shiono. Beesian Beeling (ビース星人ビーリング, Bīsu Seijin Bīringu): A lizard-themed fighter, from Planet Bees, in Durden's illegal fight club who consumes the illegal steroid Megagesterine and fights Hoji and Tetsu. Beeling is voiced by Yoshimitsu Shimoyama (下山 吉光, Shimoyama Yoshimitsu). Barigean Milibar (バリゲ星人ミリバル, Barige Seijin Miribaru): A aerokinetic cycloptic thief and serial killer from Planet Barige who previously robbed criminals to raise money for orphans before he became reckless. He enlarges himself, but is deleted by Super Dekaranger Robo. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan resurrects Milibar, who is subsequently killed by Deka Red, Blue, and Green, and Abare Yellow. Milibar is voiced by Masaru Ōbayashi (大林 勝, Ōbayashi Masaru), who also portrays his human form.
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time. Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems. Use in pregnancy and breastfeeding is of unclear safety. Liraglutide was approved for medical use in the European Union in 2009, and in the United States in 2010. It is available as a generic medication. In 2023, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
== History and etymology == Valine was first isolated from casein in 1901 by Hermann Emil Fischer. The name valine comes from its structural similarity to valeric acid, which in turn is named after the plant valerian due to the presence of the acid in the roots of the plant.
He went on to graduate school at the California Institute of Technology (Caltech) in Pasadena, California, under the guidance of Roscoe Dickinson and Richard Tolman. His graduate research involved the use of X-ray diffraction to determine the structure of crystals. He published seven papers on the crystal structure of minerals while he was at Caltech. He received his PhD in physical chemistry and mathematical physics, summa cum laude, in 1925.
The North American Bear Center, located in Ely, Minnesota, is home to the world's largest captive male and female American black bears. Ted, the male, weighed 431–453.5 kg (950–1,000 lb) in the fall of 2006. Honey, the female, weighed 219.6 kg (484 lb) in the fall of 2007.
Sources: en.wikipedia.org
== More on GRK7 == GRK7 is a member of the family of G protein-coupled receptor kinases, and is officially named G protein-coupled receptor kinase 7. GRK7 is found primarily in mammalian retinal cone cells, where it phosphorylates light-activated photopsins, members of the family of G protein-coupled receptors that recognize light of various wavelengths (red, green, blue). Phosphorylated, light-activated photopsin binds to the cone arrestin protein arrestin-4 to terminate the light-activated signaling cascade. The related GRK1, also known as rhodopsin kinase, serves a similar function in retinal rod cells subserving dim light black-and-white peripheral vision outside the fovea. The post-translational modification of GRK7 by geranylgeranylation and α-carboxyl methylation is important for regulating the ability of the enzyme to recognize color opsins in cone outer segment disk membranes. Arrestin-1 bound to rhodopsin in retinal rods prevents rhodopsin activation of the transducin protein to turn off photo-transduction completely. While cone visual transduction is much less well characterized, it is expected that arrestin-4 bound to GRK7-phosphorylated color photopsin prevents opsin activation of the transducin protein to turn off photo-transduction completely.
1,4-Dimethylamylamine (1,4-DMAA), also known as 1,4-dimethylpentylamine or as 5-methylhexan-2-amine, is a stimulant drug of the alkylamine family related to methylhexanamine (1,3-DMAA; geranamine). It is naturally present in geranium plants and has also been found in certain other plants. 1,4-DMAA has been identified in dietary supplements. It produces sympathomimetic effects in animals and humans. 1,4-DMAA and other alkylamine stimulants may act as catecholamine releasing agents. Unlike octodrine and methylhexanamine, 1,4-DMAA has never been used as a pharmaceutical drug.
=== Water === In 1998, perchlorate was included in the U.S. EPA Contaminant Candidate List, primarily due to its detection in California drinking water. In 2002, the EPA completed its draft toxicological review of perchlorate and proposed a reference dose of 0.00003 milligrams per kilogram per day (mg/kg/day) based primarily on studies that identified neurodevelopmental deficits in rat pups. These deficits were linked to maternal exposure to perchlorate. In 2003, a federal district court in California found that the Comprehensive Environmental Response, Compensation and Liability Act applied, because perchlorate is ignitable, and therefore was a "characteristic" hazardous waste. Subsequently, the U.S. National Research Council of the National Academy of Sciences (NAS) reviewed the health implications of perchlorate, and in 2005 proposed a much higher reference dose of 0.0007 mg/kg/day based primarily on a 2002 study by Greer et al. During that study, 37 adult human subjects were split into four exposure groups exposed to 0.007 (7 subjects), 0.02 (10 subjects), 0.1 (10 subjects), and 0.5 (10 subjects) mg/kg/day. Significant decreases in iodide uptake were found in the three highest exposure groups. Iodide uptake was not significantly reduced in the lowest exposed group, but four of the seven subjects in this group experienced inhibited iodide uptake. In 2005, the RfD proposed by NAS was accepted by EPA and added to its integrated risk information system (IRIS).
biosynthesis from the sulfur amino acids (e.g., cysteine); active uptake by a taurine transporter; and the extent of its release from cells by a "volume-sensitive leak pathway". Taurine is a major constituent of bile, and can be found in the large intestine. Its concentrations in land plants are low or undetectable, but up to a substantial wet weight has been found in algae.
Sources: en.wikipedia.org
== Mission personnel == Astronaut: L. Gordon Cooper, Jr. Backup Astronaut: Alan Shepard Flight Director – Red Team: Chris Kraft Flight Director – Blue Team: John Hodge Mercury Seven group: In addition to Shepard, each of the original Mercury Seven astronauts supported the orbital journey of Mercury 9 - John Glenn on a command ship near Japan, Scott Carpenter in Hawaii, Gus Grissom at a tracking station in Mexico, Wally Schirra as capsule communicator at Mercury mission control at Cape Canaveral, and Deke Slayton as an observer at the Cape. Worldwide support teams: Because MA-9 would orbit over nearly every part of the world from 32.5 degrees north to 32.5 degrees south, a total of 28 ships, 171 aircraft, and 18,000 servicemen were assigned to support the mission.
Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids. Tazarotene was approved for medical use in 1997 and is available as a generic medication.
=== Traditional medicine and research === The bark, sap, roots, leaves, seeds, and flowers are used in traditional medicine. Research has examined how it might affect blood lipid profiles and insulin secretion. Extracts from leaves contain various polyphenols, which are under basic research to determine their potential effects in humans. Despite considerable preliminary research to determine if moringa components have bioactive properties, no high-quality evidence has been found to indicate that it has any effect on health or diseases.
aqua regia A liquid mixture of nitric acid (HNO3) and hydrochloric acid (HCl), optimally in a molar ratio of 1:3, so named by historical alchemists because it is capable of dissolving the noble metals gold and platinum.
1 April – Artemis program: NASA launches the Artemis II lunar flyby mission from Launch Complex 39B at the Kennedy Space Center in Florida, the first crewed flight beyond low Earth orbit since Apollo 17 in 1972. With a crew of four astronauts – Reid Wiseman (Commander) Victor Glover (Pilot), Christina Koch (Mission specialist), and Canadian astronaut Jeremy Hansen (Mission specialist) – it also becomes the first time a person of color, a woman, and a non-United States citizen have left low Earth orbit. It passed around the Moon's far side on April 6. 2 April Scientists describe a transitional fauna of the late Ediacaran from Yunnan in China, which fills a gap between ancestors of modern phyla and larger multicellular life. Astronomers using preliminary data from the Vera C. Rubin Observatory announce the discovery of over 11,000 new asteroids, including hundreds of trans-Neptunian objects and 33 previously unknown near-Earth objects. The detections are confirmed by the Minor Planet Center. 6 April – In a landmark achievement for India's nuclear energy programme, the 500 MWe Prototype Fast Breeder Reactor successfully attains first criticality (start of controlled fission chain reaction). 6 April – The crew of Artemis II breaks the record for the furthest humans have ever been from Earth, reaching a maximum distance of 252,757 miles (406,773 km) as they travel around the far side of the Moon.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.